Targeting hexokinase 2 in castration-resistant prostate cancer

Yibin Deng; Junxuan Lu

doi:10.4161/23723556.2014.974465

Targeting hexokinase 2 in castration-resistant prostate cancer

Yibin Deng, Junxuan Lu

Hormel Institute

Research output: Contribution to journal › Comment/debate › peer-review

18 Scopus citations

Abstract

Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations.

Original language	English (US)
Article number	e974465
Journal	Molecular and Cellular Oncology
Volume	2
Issue number	3
DOIs	https://doi.org/10.4161/23723556.2014.974465
State	Published - Jul 3 2015

Bibliographical note

Funding Information:
This work was supported, in part, by grants from the US National Cancer Institute (R01 CA160333, YD; R21 CA155522, YD and JL; R01 CA172169, JL and YD), The University of Minnesota Grant-in Aid (YD) and start-up funds from The Hormel Foundation (YD).

Publisher Copyright:
© 2015, © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC. © 2015, © Yibin Deng and Junxuan Lu.

Keywords

CRPC
HK2
PTEN
Warburg effect
p53

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.4161/23723556.2014.974465

OpenUrl availability

Full text

Cite this

@article{c015364c21254c9996b7910c77bc7ad0,

title = "Targeting hexokinase 2 in castration-resistant prostate cancer",

abstract = "Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations.",

keywords = "CRPC, HK2, PTEN, Warburg effect, p53",

author = "Yibin Deng and Junxuan Lu",

note = "Funding Information: This work was supported, in part, by grants from the US National Cancer Institute (R01 CA160333, YD; R21 CA155522, YD and JL; R01 CA172169, JL and YD), The University of Minnesota Grant-in Aid (YD) and start-up funds from The Hormel Foundation (YD). Publisher Copyright: {\textcopyright} 2015, {\textcopyright} 2015 The Author(s). Published with license by Taylor & Francis Group, LLC. {\textcopyright} 2015, {\textcopyright} Yibin Deng and Junxuan Lu.",

year = "2015",

month = jul,

day = "3",

doi = "10.4161/23723556.2014.974465",

language = "English (US)",

volume = "2",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - Targeting hexokinase 2 in castration-resistant prostate cancer

AU - Deng, Yibin

AU - Lu, Junxuan

N1 - Funding Information: This work was supported, in part, by grants from the US National Cancer Institute (R01 CA160333, YD; R21 CA155522, YD and JL; R01 CA172169, JL and YD), The University of Minnesota Grant-in Aid (YD) and start-up funds from The Hormel Foundation (YD). Publisher Copyright: © 2015, © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC. © 2015, © Yibin Deng and Junxuan Lu.

PY - 2015/7/3

Y1 - 2015/7/3

N2 - Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations.

AB - Aerobic glycolysis, known as the Warburg effect, is one of the hallmarks of cancer cells. We recently reported that the hexokinase 2 (HK2)-mediated Warburg effect is required for castration-resistant prostate cancer that is driven by Pten/p53 deficiency, suggesting that HK2 might be a therapeutic target for prostate cancer patients carrying PTEN and p53 mutations.

KW - CRPC

KW - HK2

KW - PTEN

KW - Warburg effect

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=85025676935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025676935&partnerID=8YFLogxK

U2 - 10.4161/23723556.2014.974465

DO - 10.4161/23723556.2014.974465

M3 - Comment/debate

AN - SCOPUS:85025676935

SN - 2372-3556

VL - 2

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 3

M1 - e974465

ER -

Targeting hexokinase 2 in castration-resistant prostate cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this